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Vaccines based on outer membrane vesicles (OMV) were developed more than 20 years
ago against Neisseria meningitidis serogroup B. These nano-sized structures exhibit
remarkable potential for immunomodulation of immune responses and delivery of
meningococcal antigens or unrelated antigens incorporated into the vesicle structure.This
paper reviews different applications in OMV Research and Development (R&D) and pro-
vides examples of OMV developed and evaluated at the Finlay Institute in Cuba. A Good
Manufacturing Practice (GMP) process was developed at the Finlay Institute to produce
OMV from N. meningitidis serogroup B (dOMVB) using detergent extraction. Subsequently,
OMV from N. meningitidis, serogroup A (dOMVA), serogroup W (dOMVW), and serogroup
X (dOMVX) were obtained using this process. More recently, the extraction process has
also been applied effectively for obtaining OMV on a research scale from Vibrio cholerae
(dOMVC), Bordetella pertussis (dOMVBP), Mycobacterium smegmatis (dOMVSM), and BCG
(dOMVBCG). The immunogenicity of the OMV has been evaluated for specific antibody
induction, and together with functional bactericidal and challenge assays in mice has shown
their protective potential. dOMVB has been evaluated with non-neisserial antigens, includ-
ing with a herpes virus type 2 glycoprotein, ovalbumin, and allergens. In conclusion, OMV
are proving to be more versatile than first conceived and remain an important technology
for development of vaccine candidates.
Keywords: outer membrane vesicles, vaccines, proteoliposomes, adjuvant,Neisseria meningitidis,Vibrio cholerae,
Bordetella pertussis,Mycobacterium tuberculosis
INTRODUCTION
Vesicles derived from pathogens have been used for a long time in
the development of immunogenic vaccine candidates against the
respective organisms from which the vesicles have been obtained.
Proteoliposomes, outer membrane vesicles (OMV), proteasomes
(1), and very small size proteoliposomes (2) are examples of
the different approaches of vesicle formulations obtained from
microorganisms. Currently, licensed vaccines based on OMV use
detergent extraction to obtain dOMV from Gram negative bacte-
ria (3). In addition, it is possible to obtain OMV by inducing the
release of “blebs” or native OMV (nOMV) from bacteria (3). A
drawback of this latter method is that the resulting vesicles con-
tain a high amount of lipopolysaccharide (LPS), which is very toxic
(4). Therefore, several strategies are under evaluation to produce
nOMV from mutant strains containing detoxified LPS (5).
Various infectious diseases [such as tuberculosis (TB) and
meningitis] and including enteric diseases (such as cholera, sal-
monellosis, and shigellosis) remain a health problem in children
and young adults (6). No vaccines have been developed against the
responsible pathogens and the OMV strategy represents a feasible
opportunity to address this. OMV are at the interface between
traditional and new methods of vaccine production. Antigens
and immune stimulator molecules from OMV are extracted from
the pathogen and purified in proteolipidic vesicles, a reason for
also calling OMV proteoliposomes. Another approach is to use
purified molecules from bacteria and inserting them into lipidic
nanovesicles or adding any other components to the formula-
tion. Therefore, several research groups have developed structures
like proteasomes, which combine Neisseria meningitidis protein
aggregates with LPS from Shigella flexneri (1) or very small size
proteoliposomes, which combine OMV, also from N. meningi-
tidis, with the ganglioside GM3 more frequently associated with
tumor cells (2). The main goal of these nanoparticles or vesicles is
to present or deliver their load to competent cells of the immune
system (7). This mini-review examines the main developments in
various OMV technologies.
OMV VACCINES AGAINST NEISSERIA MENINGITIDIS
Meningococcal disease can occur rapidly following even mild
symptoms and can result in fatality and disability. Thus, vacci-
nation is seen as an essential strategy to prevent the rapid onset
of infection. Current vaccines against N. meningitidis have been
developed using the capsular polysaccharide of the pathogen and
have been in use since the 1960s against serogroup A and C and
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since the 1980s against serogroups A, C, Y, and W (8). These struc-
tures are highly immunogenic and can be conjugated to carrier
proteins to induce memory immune responses and immuno-
genicity in children younger than 2 years of age (9). However,
polysaccharides from the N. meningitidis serogroup B (MenB)
are low in immunogenicity and safety concerns have arisen due
to potential risks of autoimmunity (3). Therefore, novel strate-
gies, based on protein vaccines, have been developed to overcome
this hurdle. The use of wild type OMV vaccines against MenB has
been explored since the 1970s and public health interventions in
countries such as Cuba, Norway, and New Zealand have proven
the concept of their efficacy, with high effectiveness estimated in
young and adults in the region where the circulating strain was
the same as the vaccine strain (8). The Cuban VA-MENGOC-
BC® showed 83% effectiveness (over 16 months) in young and
adults (10), the Norwegian MenBVac® showed 87% effectiveness
(over 10 months) in young and adults (11), and MeNZB adminis-
tered in New Zealand, showed 73% effectiveness in the young and
adults (12). In general, estimates of vaccine efficacy in children and
infants are over 70%, although the number of doses required may
differ between each vaccine in order to keep protective immunity
for a longer period of time, e.g., the Cuban vaccine is adminis-
tered in two doses, whereas MenBVac® is given in three doses and
MeNZB® in four doses (12). These vaccines are examples of par-
enteral licensed vaccines against meningococcal B disease (details
summarized in Table 1).
The examples given above are wild type OMV vaccines,
obtained using deoxycholate detergent extraction of the bacterial
membranes. This method detoxifies and reduces the LPS con-
tent in vesicles to amounts proven to be safe by several millions
of doses of OMV vaccines administered to humans (10–12, 14).
All theses OMV vaccines have been demonstrated to be effective
against the epidemic strain, although little or no effect has been
found in infants when measuring effectiveness against heterolo-
gous strains by SBA (3), thus questioning their broad applicability
against a range of circulating MenB strains. The immunodomi-
nant antigens in N. meningitidis OMV are porins PorA and PorB
(14); there is a high variability between these proteins in strains
of the same serogroup, therefore, the immune response to OMV
is strain specific and some authors have proposed the concept of
developing “tailor-made” vaccines against the circulating strain (3,
12). On the other hand, minor proteins in OMV, non-porins, are
also responsible for the cross-protection level found in different
clinical trials (3) and different strategies, such as the recent Novar-
tis (Switzerland) Bexsero® vaccine (13) uses these minor proteins
to construct a more universal vaccine. Several proteomic tech-
niques have been developed to characterize protein antigens to aid
the selection of appropriate strains and antigens to improve the
extraction protocol (15). It is also known that detergent protocols
may not be effective in extracting some important protein antigens
such as Factor H binding protein (Fhbp), whereas other protocols
(no detergents) permit extraction and inclusion of this antigen in
the vesicles. Overall, it is very beneficial to remove endotoxins and
allow inclusion of immunogenic antigens in OMV. The advan-
tages of free detergent technologies or inclusion of recombinant
proteins to dOMV are under evaluation in new candidates and
licensed vaccines, respectively (13, 16).
The Bexsero® vaccine combines OMV that have been classi-
cally extracted by detergent and inclusion of recombinant antigens
designed by reverse vaccinology (13). The recombinant antigens
induce immune responses to a high number of serogroup B strains
and the OMV potentiate the immune response to them. Novel
strategies are envisaged to obtain OMV from recombinant N.
meningitidis strains, where LPS has been genetically detoxified
Table 1 | OMV vaccines from N. meningitidis serogroup B*.
Vaccine name Developmental history Comments Reference
VA-MENGOC-BC® Developed at the Finlay Institute, Cuba, to
address an epidemic and tested between 1987
and 1989. The strain type B:4:P1.19,15 was used
Applied in the National Immunization Program of Cuba for more
than 20 years
(3, 10)
MenBvac® Developed at the Norwegian Institute of Public
Health (NIPH) to address an epidemic and tested
between 1988 and 1991. The production strain
was the 44/76-SL, type B:15:P1.7,16
Applied in a region of Normandy, France. This technology was
used to enable development of MeNZB® and Bexsero® vaccines
(3, 11)
MeNZB® Developed against strain NZ 98/254 (strain type
B:4:P1.7-2) and used between 2004 and 2008.
The project was a partnership between the WHO,
the New Zealand government, the University of
Auckland, NIPH, and Chiron
Applied during epidemics in New Zealand. Significant partnership
development enabled a high number of clinical trials to be
carried out
(8, 12)
Bexsero® Developed by Novartis, and designed to
provide broad-based protection. Recently
licensed by the European Medicines Agency
(www.ema.europa.eu)
Combination of dOMV from strain NZ 98/254 with three
recombinant antigens, two of which are fusion proteins (targeting
five meningococcal proteins, total: the factor H-binding protein,
neisserial adhesin A, and neisserial heparin-binding antigen)
(13)
*The only OMV vaccines licensed to date.
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(lpx1-mutants), avoiding the need for detergent extraction. Fur-
thermore, mutant strains with over-expressed protein vaccine
antigens, like PorA and Fhbp, naturally inserted into the mem-
branes have been constructed (16). Certainly, a high number of
vaccine candidates with these characteristics will be seen in the
next few years.
More recently, the Finlay Institute (Cuba) and the Norwegian
Institute of Public Health (NIPH, Norway) have been working
together to develop multivalent OMV vaccines against serogroups
A (dOMVA), W (dOMVW), and X (dOMVX) (17, 18). These
serogroups represent the main cause of meningococcal disease in
Africa (19). A Phase I clinical trial commenced at the end of 2013
to evaluate the safety of a bivalent candidate against serogroups A
and W and the results are currently being examined (20). These
dOMV were obtained using epidemic strains isolated in countries
from the African “meningitis belt”: dOMVA were developed from
strain MK499/03, sequence type (ST) 5 clonal complex (cc) and
dOMVW were developed from strain MK222/02, ST11 cc (21).
All the strains belong to clonal complexes of serogroups that
caused epidemics and outbreaks several years ago (22). On the
other hand, new cases of meningococcal disease are produced by
serogroup X in countries from the African meningitis belt (23).
Based on previous experience with a combination of dOMVA and
dOMVW, both teams have begun research into a new combination
including dOMV from meningococcal serogroup X strain BF 2/97
(cc.181) (17).
OTHER APPLICATIONS
Since MenB OMV have had significant exposure to humans in clin-
ical trials, it is reasonable to assume that the safety and tolerability
profile would encourage development of other applications. Thus,
taking advantage of the immune stimulating molecules present in
OMV. Since few adjuvants are licensed for human use, it was a
reasonable concept to examine the potential of OMV for adju-
vant activity. The adjuvant potential of MenB OMV (OMVB)
have therefore been demonstrated with non-neisserial antigens
(24), including with a herpes virus type 2 glycoprotein (gD2)
(25), ovalbumin (24), and with allergens (17). With the latter
application, a formulation of dOMVB containing mite allergens
from Dermatophagoides siboney has been shown to be effective
in a preclinical trial in controlling allergic reaction (26) and is
currently undergoing a Phase I clinical trial (27). Another formu-
lation, Protollin™(Glaxo Smith Kline, GSK) has been developed
that combines N. meningitidis outer membrane proteins (OMP)
and LPS from Shigella flexneri. This formulation has been used
as an intranasal adjuvant (28) and Phase I and II clinical tri-
als have established that these vesicles are safe and well-tolerated
(29). Additionally, a clinical trial of N. meningitidis OMP mixed
only with influenza antigens (Proteasome-based influenza vac-
cine, GSK) demonstrated that the intranasal formulation was
immunogenic and well-tolerated (30).
Overall, OMV developed from N. meningitidis have been suc-
cessfully licensed or are undergoing clinical trial. Table 1 shows a
summary of the most successful dOMV evaluated against menin-
gitis. Other uses are also being found for these OMV and the
following sections highlight the advances in R&D of OMV derived
from other bacteria that demonstrate the versatility of these
structures.
OMV VACCINES AGAINST BORDETELLA PERTUSSIS
Whooping cough or pertussis is a highly contagious respiratory
disease caused by Bordetella pertussis. Despite high vaccination
coverage with whole cell or acellular vaccines, pertussis has re-
emerged not only in children, but also in adults, which can be
an additional source of infection for infants (31, 32). Among the
reasons offered to explain this resurgence is the waning of vaccine-
induced immunity and the presumed low vaccine efficacy of
acellular vaccines, which support the introduction of new vaccine
candidates to confer a protective long-lasting immunity (33).
Pertussis proteoliposomes or OMV (dOMVBP) have been con-
structed from inactivated whole cells of B. pertussis strain 165.
Characterization studies have shown that these vesicles are com-
posed of several immunogenic antigens including, pertussis toxin,
fimbriae 3, and pertactin (34). Additionally, the dOMVBP vac-
cine was highly protective against the WHO strain 18323 in
intracerebral and intranasal challenge models (34). Similarly, a
group of researchers in Argentina have obtained nOMVBP using a
detergent-free process with wild and mutant strains (35, 36); these
candidate formulations were also protective when evaluated using
an intranasal challenge model.
OMV VACCINES AGAINST ENTERIC PATHOGENS
Enteric infections induced by pathogens are one of the main causes
of death all over the world (6). The main bacterial agents are Vib-
rio cholerae, Salmonella spp., Shigella spp., and Escherichia coli.
V. cholerae O1 proteoliposomes were the first vesicles (OMVC)
obtained at the Finlay Institute from enteric pathogens. Figure 1
shows a micrograph of OMVC from Perez et al. which demon-
strated that these vesicles induced an antibody response with
vibriocidal activity when administered via the nasal route (37).
An OMVC extraction process was developed with sodium dode-
cyl sulfate (SDS) detergent to achieve maximum recovery of LPS
from the bacteria. Protein antigens with vaccine potential, such as
OmpU and MSHA, were also found in OMVC (37). In an alterna-
tive approach, Schild et al. obtained nOMVC using a detergent-free
method and demonstrated that intranasal and oral administration
of these vesicles were immunogenic and protective in a model
where the offspring of immunized female mice were infection
challenged (38).
Selection of the detergent can be a critical step for extracting
immunogenic OMV. LPS is the main antigen of enteric pathogens,
but it is also a potent toxin with differing potency in Gram neg-
ative pathogens (39); therefore, detergent and purification steps,
may differ according to the antigen that needs to be expressed
or removed from the vesicles. Recently, the production of OMV
obtained by detergent-free protocols has gained interest, because
the generation of mutant strains, hyper expressing important pro-
tein antigens, and detoxified molecules may improve the yield,
immunogenicity, and safety profile of the OMV (5, 16).
Several OMV extracts from different enteric pathogens have
been evaluated at the Finlay Institute. A multivalent formula-
tion that contained dOMV from V. cholerae, S. enteritidis, S.
typhimurium, Shigella sonnei, and S. flexneri elicited high IgG
(serum) and IgA (saliva) levels in mice and rats immunized
orally (40). Additionally, OMV from enteropathogenic (EPEC)
and enterotoxigenic (ETEC) strains of E. coli were evaluated in
mice showing high specific antibody responses and heterologous
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FIGURE 1 | Schematic representation of the dOMV extraction
process and two micrographs of OMV obtained using this
technology with two different detergents: OMV from N.
meningitidis serogroup B extracted with deoxycholate (10) and
OMV fromV. cholerae O1 extracted with sodium dodecyl sulfate
(37). OMV have a similar size and vesicle like structure. Differences
observed between micrographs are mainly due to changes in
magnification and stains used.
cross-reactivity between them (41). Camacho et al. also demon-
strated the potential of a mucosal candidate vaccine based on
nOMV from S. flexneri (42).
Acevedo et al. demonstrated that a combination of dOMVC
with polysaccharide Vi (PsVi) from S. typhi, administrated via the
nasal route, can induce immune responses at mucosal level, but
also results in systemic specific IgG anti-PsVi responses as high as
the parenteral PsVi vaccine vax-TyVi® (Finlay Institute) (43). The
potential use of combinations of different OMV or their capacity
to be combined with antigens may have important impact in the
future in the development of vaccines against enteric pathogens.
OMV VACCINES AGAINST TUBERCULOSIS
Mycobacterial extracts have been widely used in vaccine develop-
ments, including the use of Freund’s complete adjuvant (FCA),
which contains fragments from the mycobacteria. In particular,
the mycobacterial cell wall contains a variety of antigenic and
immunostimulatory molecules, such as peptidoglycan, arabino-
galactan, mycolic acids, proteins, phosphatidylinositol manno-
sides, tiocerol, lipomanann, and lipoarabinomann, which activate
dendritic cells via mannose and NOD2 receptors, among others
(44, 45). All these components are important molecular effectors
involved in the infection process and have been reported to induce
protective responses in mice against TB (46, 47).
New formulations, which are safer than FCA, but still immuno-
genic, are also under evaluation. For example, RUTI consists of
a Mycobacterium tuberculosis (MTB) protein extract and lipids,
which are delivered in liposomes (48). Preclinical experiments
show that RUTI is able to induce marked accumulation of antigen
specific IFN-γ-producing CD4+ and CD8+ T cells, whereas BCG
increases only the recruitment of CD4+ T cells. A short treat-
ment regimen with chemotherapy (isoniazid) and RUTI is under
evaluation in clinical trials. The reduction time in treatment as
well as increased efficacy in chemotherapy will impact on the
regression of the disease as well as the reduction of drug resis-
tant MTB strains (48). Another, mycobacterial derivative with
adjuvant and vaccine potential is the CAF01 formulation (49).
The mycobacterium cord factor trehalose-6,6-dimycolate and its
synthetic analog trehalose-6,6-dibehenate (TDB) are potent gly-
colipid immune stimulators that are recognized by a C-type lectin
Mincle receptor (50). This signal activates dendritic cells, leading
to cytokine production and up-regulation of co-stimulatory mol-
ecules (50). Incorporation of TDB in cationic liposomes (CAF01)
together with the recombinant fusion protein Ag85B/ESAT-6 is
a promising strategy against TB, developed by the Staten Serum
Institute (Copenhagen, Denmark) (51).
dOMV derived from non-pathogenic mycobacteria have also
been obtained. M. smegmatis and BCG have high levels of
genomic and antigenic homology with MTB (52). Therefore, it
is not surprising that proteoliposomes (dOMV) derived from
both mycobacteria have induced cross-reactive immune responses
against MTB antigens at cellular and humoral levels in mice
(52, 53). Recent results have demonstrated that these candidates
are as protective as BCG in challenge experiments conducted in
mice (54).
CONCLUSION
Outer membrane vesicles are very complex supramolecular struc-
tures. They contain immune stimulators (e.g., LPS, proteins, and
DNA) and antigenic molecules that can be delivered to immune
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competent cells of the immune system to trigger maturation
as well as activation signals. Therefore, OMV have an intrin-
sic adjuvant effect over loaded antigens from bacteria, but also
over heterologous antigens that can be incorporated or com-
bined in a single formulation. Altogether, the versatility to enable
administration via the mucosal or parenteral route offers signif-
icant choice. The adjuvant potential and increased knowledge in
the design of OMV over the last few decades will also enable
the future development of the next generation of novel vaccine
formulations.
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